D. Ouzan

V. de Lédinghen, P. Couzigou, P. Marcellin, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Possible Zoonotic Transmission of Hepatitis E from Pet Pig to Its Owner

D. Ouzan, C. Renou, M. Eloit, 2007, Emerging infectious diseases.

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.

M. Ziol, V. de Lédinghen, P. Marcellin, 2017, Gastroenterology.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients

M. Ziol, V. de Lédinghen, P. Marcellin, 2018, American heart journal.

Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Complete biochemical and histological response to therapy with ursodesoxycholic acid

D. Ouzan, C. Renou, P. Halfon, 2006, Journal of gastroenterology and hepatology.

Hepatitis C awareness among adolescents in the Alpes-Maritimes area of France.

D. Ouzan, A. Tran, R. Truchi, 2007, Gastroenterologie clinique et biologique.

Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007)

P. Marcellin, J. Pawlotsky, D. Ouzan, 2012, Antiviral therapy.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

P. Marcellin, F. Roudot-thoraval, F. Zoulim, 2016, Hepatology.

High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients.

D. Ouzan, P. Rampal, A. Tran, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity.

D. Ouzan, P. Rampal, A. Tran, 2000, Scandinavian journal of gastroenterology.

[Autoimmune thrombopenia in heroin addicts with chronic hepatopathy and positive anti-HTLV 3 serology].

D. Ouzan, A. Pesce, J. Cassuto, 1986, Presse medicale.

Detection of HBs antigen, DNA polymerase activity, and hepatitis B virus DNA in tears: relevance to hepatitis B transmission by tears.

P. Gastaud, D. Ouzan, C. Baudouin, 1989, The British journal of ophthalmology.

Melanoma in a Patient With Parkinson Disease

D. Ouzan, C. Chiaverini, J. Ortonne, 2016 .

Spread of hepatitis B virus (HBV) infection in the family members of blood donors with HBV serological markers

D. Ouzan, R. Follana, C. Tirtaine, 1991 .

Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group.

P. Marcellin, D. Ouzan, A. Tran, 1996, Journal of hepatology.

[Influence of HIV infection on hepatitis B virus infection in homosexual patients].

P. Chossegros, D. Ouzan, J. P. Heyraud, 1989, Gastroentérologie Clinique et Biologique.

Dried Blood Spot Sampling for Hepatitis B Virus Serology and Molecular Testing

D. Olive, D. Ouzan, A. Raimondo, 2013, PloS one.

Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection.

M. Chevallier, P. Chossegros, D. Ouzan, 1986, Journal of hepatology.

Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients.

J. Mouiel, D. Ouzan, J. Gugenheim, 1993, Transplantation proceedings.

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B

T. Asselah, P. Marcellin, D. Ouzan, 2020, PloS one.

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

T. Asselah, J. Pawlotsky, D. Ouzan, 2006, Gastroenterology.

Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation.

J. Mouiel, D. Ouzan, J. Gugenheim, 1999, Transplantation proceedings.

Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients

D. Ouzan, P. Halfon, G. Pénaranda, 2005, Comparative hepatology.

Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.

D. Ouzan, P. Halfon, G. Pénaranda, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation.

J. Mouiel, D. Ouzan, J. Gugenheim, 1997, Transplantation proceedings.

[Superiority of a new etiopathogenic treatment curing periarteritis nodosa caused by hepatitis B virus, using a combination of brief corticotherapy, vidarabine and plasma exchange].

D. Ouzan, J. Delmont, C. Trepo, 1988, Presse medicale.

[Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study].

P. Marcellin, M. Chevallier, P. Chossegros, 1987, Gastroenterologie clinique et biologique.

Recurrence of hepatitis C virus after liver transplantation

J. Mouiel, D. Ouzan, J. Gugenheim, 1994, Transplant international : official journal of the European Society for Organ Transplantation.

Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.

P. Marcellin, D. Ouzan, T. Fontanges, 2008, World journal of gastroenterology.

HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon

T. Asselah, D. Ouzan, G. Kukolj, 2014 .

531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE

P. Marcellin, X. Causse, F. Zoulim, 2012 .

Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: Implications for clinical management of patients with chronic hepatitis C virus infection

D. Ouzan, P. Halfon, M. Bourlière, 2006, Journal of medical virology.

Large-Scale Screening of Lipase Acid Deficiency in at Risk Population.

V. de Lédinghen, M. Krempf, D. Ouzan, 2021, Clinica chimica acta; international journal of clinical chemistry.

A French prospective observational study of the treatment of chronic hepatitis C in drug abusers.

P. Couzigou, P. Chossegros, D. Ouzan, 2008, Gastroenterologie clinique et biologique.

[Viral replication and hepatic manifestations in 7 cases of periarteritis nodosa associated with hepatitis B virus].

D. Ouzan, C. Trepo, 1986, Gastroenterologie clinique et biologique.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

V. de Lédinghen, F. Zoulim, D. Ouzan, 2017, Journal of hepatology.

Prevalence of GBV C/HGV RNA and GBV C/HGV Antibodies in French Volunteer Blood Donors: Results of a Collaborative Study

P. de Micco, D. Ouzan, R. Césaire, 1999, Vox Sanguinis.

Prevalence of transmitted transfusion virus (TTV) in populations at different risk for hepatitis virus: hemodialysis, chronic hepatitis C and cryptogenetic hepatitis patients.

D. Ouzan, P. Halfon, M. Bourlière, 1999, Journal of hepatology.

Hepatitis C Virus Genotyping Based on 5′ Noncoding Sequence Analysis (Trugene)

V. de Lédinghen, P. Couzigou, D. Ouzan, 2001, Journal of Clinical Microbiology.

Noncoding Sequence Analysis ( Trugene ) ′ Hepatitis C Virus Genotyping Based on 5

P. Couzigou, D. Ouzan, H. Fleury, 2001 .

Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study

T. Asselah, F. Zoulim, D. Ouzan, 2017, European journal of gastroenterology & hepatology.

Transmission of hepatitis G virus in HCV-infected couples: myth or reality?

D. Ouzan, P. Halfon, M. Bourlière, 1997, Journal of hepatology.

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

V. Paradis, D. Ouzan, C. Degott, 2007, Journal of hepatology.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

V. de Lédinghen, S. Imbeaud, J. Zucman‐Rossi, 2018, Gastroenterology.

[Efficacy of adenine arabinoside (vidarabine) in the treatment of periarteritis nodosa associated with chronic active viral hepatitis B].

P. Bauret, D. Ouzan, H. Michel, 1986, Gastroenterologie clinique et biologique.

Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus

Albert Tran, D. Ouzan, A. Tran, 2005, Comparative hepatology.

A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa‐2a (40kD)/ribavirin

D. Ouzan, D. Delić, P. Ferenci, 2014, Liver international : official journal of the International Association for the Study of the Liver.

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

A. Mangia, D. Ouzan, J. Gervain, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy

P. Schnyder, D. Ouzan, A. Denys, 2004, European Radiology.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Albert Tran, Vincent Leroy, Dominique Larrey, 2018, Gastroenterology.

Hepatic abscesses and "sump syndrome": a new case.

F. Prat, D. Ouzan, C. Trepo, 1989, Endoscopy.

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

T. Asselah, D. Ouzan, J. Dufour, 2013 .

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.

M. Ziol, V. de Lédinghen, J. Zucman‐Rossi, 2022, Journal of hepatology.

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

T. Asselah, P. Marcellin, D. Ouzan, 2016 .

Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study.

D. Ouzan, T. Fontanges, S. Pol, 2007, Gastroenterologie clinique et biologique.

Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

I. Ntalla, H. Ramroth, F. Carrat, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, F. Roudot-thoraval, 2015, Gut.

Independent Prospective Multicenter Validation of Biochemical Markers (Fibrotest–Actitest) for the Prediction of Liver Fibrosis and Activity in Patients with Chronic Hepatitis C: The Fibropaca Study

Albert Tran, D. Ouzan, C. Degott, 2006, The American Journal of Gastroenterology.

Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study.

V. de Lédinghen, D. Ouzan, D. Larrey, 2019, Annals of hepatology.

[Risk of transmission of hepatitis C virus by digestive endoscopy].

J. Rey, D. Ouzan, P. Halfon, 1995, Gastroenterologie clinique et biologique.

[Plasma exchange and acyclovir in Behçet's disease].

D. Ouzan, M. Bonnet, C. Trepo, 1986, Journal francais d'ophtalmologie.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

V. de Lédinghen, P. Marcellin, E. Letouzé, 2018, Hepatology.

Management of chronic hepatitis C in French departments of internal medicine and infectious diseases

F. Carrat, D. Ouzan, P. Morlat, 2005, Epidemiology and Infection.

Protective effects of prostaglandin E1 on normothermic liver ischemia.

J. Mouiel, D. Ouzan, J. Gugenheim, 1991, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

High prevalence of hepatitis E virus antibody in haemodialysis patients

D. Ouzan, P. Halfon, H. Khiri, 1994, The Lancet.

[Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes region].

D. Ouzan, N. Cohen, R. Follana, 2000, Gastroenterologie clinique et biologique.

Un point de vue pluridisciplinaire sur l’infection par le VHC

D. Ouzan, P. Cacoub, L. Cattan, 2004 .

Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma

D. Ouzan, A. Leysalle, M. Benchetrit, 2020, Therapeutic advances in gastroenterology.

Orthotopic liver transplantation with and without peritoneal drainage: a comparative study.

J. Mouiel, D. Ouzan, J. Gugenheim, 1999, Transplantation proceedings.

P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

P. Marcellin, X. Causse, F. Zoulim, 2014 .

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, S. Chevret, 2015, Hepatology.

Hepatitis G Virus (HGV) and Antibodies to a Putative HGV Envelope Protein in Alcoholic Patients in South-Eastern France

D. Ouzan, P. Rampal, A. Tran, 1998, American Journal of Gastroenterology.

Lack of influence of hepatitis G virus infection on alcohol-related hepatic lesions.

D. Ouzan, P. Rampal, A. Tran, 1998, Scandinavian journal of gastroenterology.

Portal and mesenteric thrombosis revealing constitutional protein C deficiency.

F. Prat, D. Ouzan, C. Trepo, 1989, Gut.

Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

V. de Lédinghen, T. Asselah, D. Thabut, 2021, JHEP Reports.

Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

D. Ouzan, A. Tran, C. Renou, 2008, Alimentary pharmacology & therapeutics.

Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort

P. Marcellin, E. Letouzé, D. Thabut, 2019, Journal of viral hepatitis.

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

T. Asselah, D. Ouzan, T. Hassanein, 2016, Annals of hepatology.

Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.

D. Ouzan, P. Halfon, G. Pénaranda, 2013, Journal of hepatology.

Comparison of high initial and fixed‐dose regimens of interferon‐α2a in chronic hepatitis C: a randomized controlled trial

D. Ouzan, D. Valla, P. Opolon, 1998 .

HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management

V. de Lédinghen, T. Asselah, F. Zoulim, 2021, Cancer Prevention Research.

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono‐infected compared with HIV–HCV co‐infected patients

F. Carrat, D. Ouzan, P. Bedossa, 2009, Alimentary pharmacology & therapeutics.

Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors

F. Zoulim, D. Ouzan, C. Scholtès, 2016 .

Serological response to infection with different isolates of hepatitis C virus.

D. Ouzan, P. Halfon, H. Khiri, 2002, Journal of Viral Hepatitis.

An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study)

X. Causse, D. Ouzan, P. Sogni, 2022, Health science reports.

[Registry of liver biopsies from hepatitis C infected patients in the Alpes-Maritimes (France). Results from the first 2 years].

D. Ouzan, P. Rampal, A. Tran, 2008, Gastroenterologie clinique et biologique.

[Screening and hepatitis C management survey in general medicine in the Alpes-Maritimes and east Var area].

D. Ouzan, A. Tran, P. Cavailler, 2003, Gastroenterologie clinique et biologique.

Hepatitis C virus infection and lymphoproliferative diseases in France: a national study. The GERMIVIC Group.

J. Piette, D. Ouzan, P. Cacoub, 2000, American journal of hematology.

833 LIVER FIBROSIS ASSESSMENT IN CHRONIC HEPATITIS C: EVOLUTION OF CLINICAL PRACTICE IN A LARGE COHORT OF 4546 PATIENTS BETWEEN 2003 AND 2006

P. Marcellin, F. Roudot-thoraval, D. Ouzan, 2008 .

Serotyping and genotyping of hepatitis C virus (HCV) strains in chronic HCV infection

D. Ouzan, P. Halfon, H. Khiri, 1997, Journal of medical virology.

Les outils du diagnostic de l'infection par le virus de l'hépatite C : Prise en charge pluridisciplinaire de l'infection par le virus de l'hépatite C

D. Ouzan, P. Cacoub, P. Halfon, 2004 .

Serological response to infection with different isolates of hepatitis C virus

D. Ouzan, P. Halfon, M. Bourlière, 2002 .

Anti-GOR and anti-thyroid autoantibodies in patients with chronic hepatitis C.

D. Ouzan, A. Tran, S. Benzaken, 1995, Clinical Immunology and Immunopathology.

Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay

D. Ouzan, D. Sène, P. Cacoub, 2008, Journal of Clinical Microbiology.

[Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B].

P. Marcellin, D. Ouzan, A. Tran, 1998, Ugeskrift for læger.

Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)

J. Zucman‐Rossi, P. Marcellin, E. Letouzé, 2016 .

High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials

P. Marcellin, A. Mangia, D. Ouzan, 2012, Hepatology.

2014 French guidelines for hepatitis B and C screening. A combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV

Y. Yazdanpanah, F. Roudot-thoraval, D. Dhumeaux, 2016 .

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, S. Chevret, 2015, Hepatology.

Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007)

P. Marcellin, J. Pawlotsky, D. Ouzan, 2012, Antiviral therapy.

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)

V. de Lédinghen, J. Zucman‐Rossi, D. Thabut, 2023, Quality of Life Research.

[Sclerosing cholangitis caused by sterilization of a hydatid cyst of the liver with a hypertonic saline solution].

F. Prat, D. Ouzan, C. Trepo, 1988, Gastroenterologie clinique et biologique.

Iconographies supplémentaires de l'article : Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection

D. Ouzan, T. Fontanges, B. Filoche, 2008 .